1 Powerhouse Drug in Celgene's Pipeline

To kick things off at this week's BIO CEO conference, conducted by the Biotech Industry Organization, Celgene's CEO Bob Hugin gave a fireside chat. In this video, Motley Fool health care bureau chief Brenton Flynn highlights one of the topics discussed -- the company's new inflammation drug Apremilast -- and one of the biggest reasons why this could be a winner over the existing crop of TNF inhibitors.

Is Celgene still a buy?
With Celgene's broad portfolio of drugs and a strong pipeline to boot, many investors see it as a smarter way to play the biotech investing game. While Celgene might be a safer stock than its small biotech brethren, investors need to know about the key opportunities and risks facing the company. We run through them all in The Motley Fool's brand new premium report on Celgene. To claim your copy today, simply click here now.

The article 1 Powerhouse Drug in Celgene's Pipeline originally appeared on Fool.com.

Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.